Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes
- PMID: 2015597
Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes
Abstract
Cryopreserved and thawed lymphocytes can be used instead of fresh lymphocytes to avoid test-to-test variability in studies of fluctuations of natural killer (NK) and lymphokine-activated killer (LAK) activities as a function of time. We investigated the effects of 1-h versus 18-h resting of lymphocytes on their lytic activities, because the process of cryopreservation and thawing decreases NK and LAK activities. Lymphocytes from renal cell cancer patients receiving adoptive immunotherapy were studied. An 18-h versus 1-h resting period led to a significant increase in NK activity but had no significant effect on LAK activity. The presence of 1200 IU/ml interleukin 2 (IL-2) in the medium 1 h prior to and during the cytotoxicity (CTX) assay increased in vivo and in vitro IL-2-induced LAK activities. This phenomenon has been interpreted as IL-2 dependency of effector lymphocytes (J.A. Hank, P.C. Kohler, G. Weil-Hillman, N. Rosenthal, K. H. Moore, B. Storer, D. Minkoff, J. Bradshaw, R. Bechhofer, and P. M. Sondel. Cancer Res., 48: 1965-1971, 1988). We performed kinetic studies to assess the role of effector lymphocyte recruitment in these experiments. LAK activity was tested in the presence or absence of IL-2 during preincubations and CTX assays varying between 0 and 120 min. These kinetic studies showed that effector lymphocyte recruitment indeed contributed to the increased level of LAK activity when IL-2 was added to the CTX assay. A minimal incubation period of 30 min was required to detect recruitment of lymphocytes. Effector lymphocytes could be recruited for periods varying between 90 and greater than 240 min, depending on the lymphocyte donor. We conclude that: (a) in vitro, IL-2-mediated recruitment of lymphocytes due to presence of IL-2 in the CTX assay may lead to an overestimate of the actual LAK activity; and (b) in vivo, prolonged IL-2 infusion after the administration of activated lymphocytes seems warranted in order to recruit maximal levels of effector lymphocytes with LAK activity.
Similar articles
-
Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.In Vivo. 1999 May-Jun;13(3):199-204. In Vivo. 1999. PMID: 10459491
-
Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.J Biol Response Mod. 1990 Dec;9(6):546-55. J Biol Response Mod. 1990. PMID: 2074441 Clinical Trial.
-
Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.Bone Marrow Transplant. 1997 Mar;19(6):545-51. doi: 10.1038/sj.bmt.1700698. Bone Marrow Transplant. 1997. PMID: 9085733
-
[Interactions and biological mechanisms of action of molecular signal peptides. II. Interleukin 2 (IL-2)].HNO. 1991 Sep;39(9):323-31. HNO. 1991. PMID: 1836210 Review. German.
-
Lymphokine activated killer cells.Blut. 1989 Oct;59(4):375-84. doi: 10.1007/BF00321208. Blut. 1989. PMID: 2676022 Review.
Cited by
-
Synergistic effect of interleukin-2 and a vaccine of irradiated melanoma cells transfected to secrete staphylococcal enterotoxin A.Clin Exp Metastasis. 2002;19(1):43-53. doi: 10.1023/a:1013875104326. Clin Exp Metastasis. 2002. PMID: 11918082
-
Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon alpha.Cancer Immunol Immunother. 1993 Jul;37(1):40-6. doi: 10.1007/BF01516940. Cancer Immunol Immunother. 1993. PMID: 8513451 Free PMC article.
-
Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction.J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):32-44. doi: 10.1002/jcsm.12009. Epub 2015 Mar 31. J Cachexia Sarcopenia Muscle. 2015. PMID: 26136410 Free PMC article.
-
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.Br J Cancer. 2004 Mar 8;90(5):985-90. doi: 10.1038/sj.bjc.6601617. Br J Cancer. 2004. PMID: 14997194 Free PMC article. Clinical Trial.
-
Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.Br J Cancer. 1993 Jan;67(1):163-71. doi: 10.1038/bjc.1993.29. Br J Cancer. 1993. PMID: 7678979 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical